Pub. Date : 2020 Aug
PMID : 31707688
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. | Ralimetinib | mitogen-activated protein kinase 14 | Homo sapiens |
| 2 | A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer. | Ralimetinib | mitogen-activated protein kinase 14 | Homo sapiens |
| 3 | Purpose The primary objective was to determine the recommended Phase 2 dose (RP2D) of checkpoint kinase 1 inhibitor, prexasertib, in combination with the p38 mitogen-activated protein kinase inhibitor, ralimetinib, which may be safely administered to patients with advanced cancer. | Ralimetinib | mitogen-activated protein kinase 14 | Homo sapiens |